Results 11 to 20 of about 18,326 (214)

Development of Deferoxamine‐Functionalized Cyclodextrin Polymer for Targeted Iron Chelation

ChemistryOpen
Polymeric systems are used in clinical settings to bind small molecules and ions. They show advantages in pharmacokinetics and reduced side effects compared to low‐molecular‐weight agents.
Roberta Panebianco, Maurizio Viale, Graziella Vecchio   +2 more
doaj   +2 more sources

Deferoxamine Compensates for Decreases in B Cell Counts and Reduces Mortality in Enterovirus 71-Infected Mice

Marine Drugs, 2014
Enterovirus 71 is one of the major causative agents of hand, foot and mouth disease in children under six years of age. No vaccine or antiviral therapy is currently available.
Yajun Yang, Jing Ma, Jinghui Xiu, Lin Bai, Feifei Guan, Li Zhang, Jiangning Liu, Lianfeng Zhang   +7 more
doaj   +2 more sources

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

Journal of Cardiovascular Magnetic Resonance, 2012
Background Combination therapy with deferoxamine and oral deferiprone is superior to deferoxamine alone in removing cardiac iron and improving left ventricular ejection fraction (LVEF).
Alpendurada Francisco, Smith Gill C, Carpenter John-Paul, Nair Sunil V, Tanner Mark A, Banya Winston, Dessi Carlo, Galanello Renzo, Walker John, Pennell Dudley J   +9 more
doaj   +2 more sources

Application of Deferoxamine in Tissue Regeneration Attributed to Promoted Angiogenesis

Molecules
Deferoxamine, an iron chelator used to treat diseases caused by excess iron, has had a Food and Drug Administration-approved status for many years. A large number of studies have confirmed that deferoxamine can reduce inflammatory response and promote ...
Haijun Shen, Yane Ma, Yi Qiao, Chun Zhang, Jialing Chen, Ran Zhang   +5 more
doaj   +2 more sources

Improving adherence with deferoxamine regimen in thalassemia major using education

Iranian South Medical Journal, 2006
Background: Subcutaneous deferoxamine is the first line for management of iron overload in thalassemia major. There is a wide deferoxamine adherence variation in patients with thalassemia major.
Gholamreza Pouladfar, Mandana Moaiedfard
doaj   +1 more source

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior

Caspian Journal of Internal Medicine, 2017
Background: Cardiac complications due to iron overload are the most common cause of death in patients with thalassemia major. The aim of this study was to compare iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and ...
Shahla Ansari, Azita Azarkeivan, Ghasem Miri-Aliabad, Saeed Yousefian, Tahereh Rostami   +4 more
doaj   +1 more source

Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson’s Disease Mice [PDF]

International Journal of Nanomedicine
Yiming Huang,1,* Xinran Wang,1,* Wenjing Li,1,* Feng Yue,1,2 Miao Wang,1 Feifan Zhou1,2 1State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Sanya, People’s Republic of China; 2One Health ...
Huang Y, Wang X, Li W, Yue F, Wang M, Zhou F   +5 more
doaj   +1 more source

Deferoxamine deconditioning increases neuronal vulnerability to hemoglobin

, 2020
Hypothesis: Deferoxamine pretreatment and abrupt withdrawal increases the vulnerability of neurons to hemoglobin. Model: Primary cortical cell cultures (murine); cultures were pretreated with deferoxamine alone, deferoxamine plus hemoglobin, or vehicle ...
Regan, R (via Mendeley Data)
core   +3 more sources

Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity [PDF]

, 2020
Background: Reduced glutathione and excess free iron within dopaminergic, substantia nigra neurons in Parkinson's disease (PD) can drive accumulation of toxic hydroxyl radicals resulting in sustained oxidative stress and cellular damage.
Zariwala, M., Mursaleen, L., Somavarapu, S.   +2 more
core   +1 more source

Reduced sulfatide content in deferoxamine-induced senescent HepG2 cells [PDF]

, 2023
Iron chelators, such as deferoxamine, exert an anticancer effect by altering the activity of biomolecules critical for regulation of the cell cycle, cell metabolism, and apoptotic processes.
Bresci, Arianna, Polli, Dario, Ghislanzoni, Silvia, Sarcinelli, Gaia Martina, Maria Teresa Radice, Italia Bongarzone, Tomassetti, Antonella, Francesco Manetti, Manetti, Francesco, Silvia Ghislanzoni, Dario Polli, Gaia Martina Sarcinelli, Bongarzone, Italia, Radice, Maria Teresa, Arianna Bresci, Antonella Tomassetti   +15 more
core   +1 more source